Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Hirose Y, Shindo N, Mori M, Onitsuka S, Isogai H, Hamada R, Hiramoto T, Ochi J, Takahashi D, Ueda T, Caaveiro JMM, Yoshida Y, Ohdo S, Matsunaga N, Toba S, Sasaki M, Orba Y, Sawa H, Sato A, Kawanishi E, Ojida A. Hirose Y, et al. Among authors: kawanishi e. J Med Chem. 2022 Oct 27;65(20):13852-13865. doi: 10.1021/acs.jmedchem.2c01081. Epub 2022 Oct 13. J Med Chem. 2022. PMID: 36229406
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y, Tanaka Y, Matsumura T, Kadoh Y, Miyoshi H, Hongu M, Takedomi K, Kotera J, Sasaki T, Taniguchi H, Watanabe Y, Takakuwa M, Kojima K, Baba N, Nakamura I, Kawanishi E. Koizumi Y, et al. Among authors: kawanishi e. Bioorg Med Chem. 2019 Aug 1;27(15):3440-3450. doi: 10.1016/j.bmc.2019.06.021. Epub 2019 Jun 19. Bioorg Med Chem. 2019. PMID: 31235264
Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y, Miyoshi H, Matsumura T, Tanaka Y, Hongu M, Kimura M, Takedomi K, Omori K, Kotera J, Sasaki T, Kobayashi T, Taniguchi H, Watanabe Y, Kojima K, Sakamoto T, Himiyama T, Kawanishi E. Kadoh Y, et al. Among authors: kawanishi e. Chem Pharm Bull (Tokyo). 2018;66(3):243-250. doi: 10.1248/cpb.c17-00783. Chem Pharm Bull (Tokyo). 2018. PMID: 29491258 Free article.
Baseline feature of a randomized trial assessing the effects of disease management programs for the prevention of recurrent ischemic stroke.
Fukuoka Y, Hosomi N, Hyakuta T, Omori T, Ito Y, Uemura J, Kimura K, Matsumoto M, Moriyama M; DMP Stroke Trial Investigators. Fukuoka Y, et al. J Stroke Cerebrovasc Dis. 2015 Mar;24(3):610-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.10.007. Epub 2015 Jan 6. J Stroke Cerebrovasc Dis. 2015. PMID: 25576351 Free article. Clinical Trial.
Phosphodiesterase 10A PET radioligand development program: from pig to human.
Plisson C, Weinzimmer D, Jakobsen S, Natesan S, Salinas C, Lin SF, Labaree D, Zheng MQ, Nabulsi N, Marques TR, Kapur S, Kawanishi E, Saijo T, Gunn RN, Carson RE, Rabiner EA. Plisson C, et al. Among authors: kawanishi e. J Nucl Med. 2014 Apr;55(4):595-601. doi: 10.2967/jnumed.113.131409. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614221 Free article.
23 results